Myeloproliferative disorders and the hyperviscosity syndrome

Hematology/Oncology Clinics of North America

Volumn 24, Issue 3, 2010, Pages 585-602

  Adams, Bruce D ^a,b   Baker, Russell ^c   Lopez, J Abraham ^c   Spencer, Susan ^c  

^a WILLIAM BEAUMONT ARMY MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c Texas Tech University Health Sciences Center El Paso   (United States)

Author keywords

Essential thrombocytosis; Hyperleukocytosis; Hyperviscosity syndrome; Leukostasis; Polycythemia vera; Waldenstrom macroglobulinemia

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; CHLORAMBUCIL; HYDROXYUREA; PHOSPHORUS 32; PROTON PUMP INHIBITOR; RECOMBINANT ALPHA INTERFERON;

BLEEDING; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; ERYTHROCYTOSIS; HUMAN; HYPERVISCOSITY SYNDROME; HYPOCALCEMIA; LABORATORY DIAGNOSIS; LEUKAPHERESIS; LEUKOCYTOSIS; LEUKOSTASIS; LONG TERM CARE; LOW DRUG DOSE; MACROCYTIC ANEMIA; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEUTROPENIA; PATHOPHYSIOLOGY; PHLEBOTOMY; PLASMAPHERESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SKIN ULCER; TERATOGENICITY; THROMBOCYTOPHERESIS; THROMBOCYTOSIS; THROMBOEMBOLISM; THROMBOSIS; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

EID: 77952949493     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.03.004     Document Type: Review

References (113)

1. Bekelman J., Jackson N., Donehower R.C. Oncologic emergencies. The Osler medical handbook 2006, Saunders Elsevier, Philadelphia. 2nd edition. K.R. Nilsson, J.P. Piccini (Eds.).
2. Zojer N., Ludwig H. Hematological emergencies. Ann Oncol 2007, 1(Suppl 18):i45-i48.
3. Frewin R., Henson A., Provan D. ABC of clinical haematology. Haematological emergencies. BMJ 1997, 314(7090):1333-1336.
4. Mehta J., Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias. Semin Thromb Hemost 2003, 29(5):467-471.
5. Nkwuo N., Schamban N., Borenstein M. Selected oncologic emergencies. Rosen's emergency medicine: concepts and clinical practice 2006, Mosby, Philadelphia. J.A. Marx (Ed.).
6. Vijay A., Gertz M.A. Waldenstrom macroglobulinemia. Blood 2007, 109(12):5096-5103.
7. Rajkumar V.S., Dispenzieri A.S., Kyle R.A. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc 2006, 81(5):693-703.
8. McPherson R.A., Pincus M.R. Henry's clinical diagnosis and management by laboratory methods 2006, W.B. Saunders, Philadelphia. 21st edition.
9. Mullen E.C., Wang M. Recognizing hyperviscosity syndrome in patients with Waldenstrom macroglobulinemia. Clin J Oncol Nurs 2007, 11(1):87-95.
10. Shaheen S.P., Talwalkar S.S., Medeiros L.J., et al. Multiple myeloma and immunosecretory disorders: an update. Adv Anat Pathol 2008, 15(4):196-210.
11. Garderet L., Fabiani B., Lacombe K., et al. Hyperviscosity syndrome in an HIV-1-positive patient. Am J Med 2004, 117(11):891-893.
12. Chu K., Kang D.W., Kim D.E., et al. Magnetic resonance findings of hemichorea-hemiballismus associated with diabetic hyperglycemia: a hyperviscosity syndrome?. Arch Neurol 2002, 59(3):448-452. [miscellaneous article].
13. Paul B. Polyclonal hypergammaglobulinaemia with hyperviscosity syndrome. Br J Haematol 2002, 118(3):922-923.
14. Kesmarky G., Kenyeres P., Rabai M., et al. Plasma viscosity: a forgotten variable. Clin Hemorheol Microcirc 2008, 39(1-4):243-246.
15. Rosencranz R., Bogen S.A. Clinical laboratory measurement of serum, plasma, and blood viscosity. Am J Clin Pathol 2006, 125(Suppl):S78-S86.
16. Winters J.L., Pineda A.A. Hemapheresis. Henry's clinical diagnosis and management by laboratory methods 2006, W.B. Saunders Company, Philadelphia. 21st editon. R.A. McPherson, M.R. Pincus (Eds.).
17. Ramsakal A., Beaupre D. Cancer emergencies: hyperviscosity syndromes. Comprehensive hospital medicine 2007, Saunders, Philadelphia. M.V. Williams (Ed.).
18. Eby C., Blinder M. Hemostatic complications associated with paraproteinemias. Curr Hematol Rep 2003, 2(5):388-394.
19. Menke M.N., Feke G.T., McMeel J.W., et al. Hyperviscosity-related retinopathy in Waldenstrom macroglobulinemia. Arch Ophthalmol 2006, 124(11):1601-1606.
20. Syms M.J., Arcila M.E., Holtel M.R. Waldenstrom's macroglobulinemia and sensorineural hearing loss. Am J Otol 2001, 22(5):349-353.
21. Vitolo U., Ferreri A.J., Montoto S., et al. Lymphoplasmacytic lymphoma - Waldenstrom's macroglobulinemia. Crit Rev Oncol Hematol 2008, 67(2):172-185.
22. Higdon M.L., Higdon J.A. Treatment of oncologic emergencies. Am Fam Physician 2006, 74(11):1873-1880.
23. Burwick N., Roccaro A.M., Leleu X., et al. Targeted therapies in Waldenstrom macroglobulinemia. Curr Opin Investig Drugs 2008, 9(6):631-637.
24. Goldschmidt H., Lannert H., Bommer J., et al. Multiple myeloma and renal failure. Nephrol Dial Transplant 2000, 15(3):301-304.
25. Dimopoulos M.A., Kastritis E., Rosinol L., et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008, 22(8):1485-1493.
26. Sharma B.D., Kabra S.R., Gupta B. Symmetrical peripheral gangrene. Trop Doct 2004, 34(1):2-4.
27. Bain B.J. Diagnosis from the blood smear. N Engl J Med 2005, 353(5):498-507.
28. Weinstein R., Mahmood M. Case 6-2002- a 54-year-old woman with left, then right, central-retinal-vein occlusion. N Engl J Med 2002, 346(8):603-610.
29. McKenna J.A. Waldenstrom's macroglobulinemia. Clin J Oncol Nurs 2002, 6(5):283-286.
30. Teruya J. Practical issues in therapeutic apheresis. Ther Apher 2002, 6(4):288-289.
31. Johnson S.A. Advances in the treatment of Waldenstrom's macroglobulinemia. Expert Rev Anticancer Ther 2006, 6(3):329-334.
32. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 2008, 83(6):491-497.
33. Prchal J.T. Polycythemia vera and other primary polycythemias. Curr Opin Hematol 2005, 12(2):112-116.
34. Lorberboym M., Rahimi-Levene N., Lipszyc H., et al. Analysis of red cell mass and plasma volume in patients with polycythemia. Arch Pathol Lab Med 2005, 129(1):89-91.
35. Dams K., Meersseman W., Verbeken E., et al. A 59-year-old man with shock, polycythemia, and an underlying paraproteinemia. Chest 2007, 132(4):1393-1396.
36. Tefferi A., Spivak J.L. Polycythemia vera: scientific advances and current practice. Semin Hematol 2005, 42(4):206-220.
37. Lippert E., Boissinot M., Kralovics R., et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006, 108(6):1865-1867.
38. Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007, 356(5):459-468.
39. Schafer A.I. Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006, 107(11):4214-4222.
40. Halperin M.L., Cheema-Dhadli S., Lin S.H., et al. Properties permitting the renal cortex to be the oxygen sensor for the release of erythropoietin: clinical implications. Clin J Am Soc Nephrol 2006, 1(5):1049-1053.
41. Hodges V.M., Rainey S., Lappin T.R., et al. Pathophysiology of anemia and erythrocytosis. Crit Rev Oncol Hematol 2007, 64(2):139-158.
42. Takeda K., Aguila H.L., Parikh N.S., et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 2008, 111(6):3229-3235.
43. Finazzi G., Gregg X.T., Barbui T., et al. Idiopathic erythrocytosis and other non-clonal polycythemias. Best Pract Res Clin Haematol 2006, 19(3):471-482.
44. Mossuz P., Girodon F., Donnard M., et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004, 89(10):1194-1198.
45. Spivak J.L., Silver R.T. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood 2008, 112(2):231-239.
46. Prchal J.T., Pastore Y.D. Erythropoietin and erythropoiesis: polycythemias due to disruption of oxygen homeostasis. Hematol J 2004, 5(Suppl 3):S110-S113.
47. Gordeuk V.R., Prchal J.T. Vascular complications in Chuvash polycythemia. Semin Thromb Hemost 2006, 32(3):289-294.
48. Gordeuk V.R., Stockton D.W., Prchal J.T. Congenital polycythemias/erythrocytoses. Haematologica 2005, 90(1):109-116.
49. Lee Y.-S., Vortmeyer A.O., Lubensky I.A., et al. Coexpression of erythropoietin and erythropoietin receptor in von Hippel-Lindau disease-associated renal cysts and renal cell carcinoma. Clin Cancer Res 2005, 11(3):1059-1064.
50. Windsor J.S., Rodway G.W. Heights and haematology: the story of haemoglobin at altitude. Postgrad Med J 2007, 83(977):148-151.
51. Tefferi A., Thiele J., Orazi A., et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007, 110(4):1092-1097.
52. Tefferi A., Vardiman J.W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2007, 22(1):14-22.
53. Landolfi R., Marchioli R., Kutti J., et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004, 350(2):114-124.
54. Finazzi G., Barbui T. How I treat patients with polycythemia vera. Blood 2007, 109(12):5104-5111.
55. Tefferi A. Polycythemias. Cecil's medicine 2007, Saunders, Philadelphia. 23rd edition. L. Goldman, D. Ausiello (Eds.).
56. Hamilton G.C., Janz T.J. Anemia, polycythemia, and white blood cell disorders. Rosen's emergency medicine: concepts and clinical practice 2006, Mosby, Philadelphia. J.A. Marx (Ed.).
57. Hoffman R., Benz E.J., Shattil S.J., et al. Hematology: basic principles and practice 2005, Elsevier, Philadelphia.
58. Porcu P., Cripe L.D., Ng E.W., et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 2000, 39(1-2):1-18.
59. Porcu P., Farag S., Marcucci G., et al. Leukocytoreduction for acute leukemia. Ther Apher 2002, 6(1):15-23.
60. Nowacki P., Zdziarska B., Fryze C., et al. Co-existence of thrombocytopenia and hyperleukocytosis ('critical period') as a risk factor of haemorrhage into the central nervous system in patients with acute leukaemias. Haematologia 2002, 31(4):347-355.
61. Pui C.H., Robison L.L., Look A.T., et al. Acute lymphoblastic leukaemia. Lancet 2008, 371(9617):1030-1043.
62. Leis J.F., Primack S.L., Schubach S.E., et al. Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis. Haematologica 2004, 89(9):102-103.
63. Hamilton G., Janz T. Anemia, polycythemia, and white blood cell disorders. Emergency medicine concepts and clinical practice 2006, 1867-1891. Mosby, Philadelphia. P. Rosen (Ed.).
64. Sakka V., Tsiodras S., Giamarellos-Bourboulis E.J., et al. An update on the etiology and diagnostic evaluation of a leukemoid reaction. Eur J Intern Med 2006, 17(6):394-398.
65. Halfdanarson T.R., Hogan W.J., Moynihan T.J., et al. Oncologic emergencies: diagnosis and treatment. Mayo Clin Proc 2006, 81(6):835-848.
66. Kwaan H., Vicuna B. Thrombosis and bleeding in cancer patients. Oncology Review 2007, 1(1):14-27.
67. Lawrence Y.R., Raveh D., Rudensky B., et al. Extreme leukocytosis in the emergency department. QJM 2007, 100(4):217-223.
68. Sadeghi-Nejad H., Dogra V., Seftel A.D., et al. Priapism. Radiol Clin North Am 2004, 42(2):427-443.
69. Stucki A., Rivier A.S., Gikic M., et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001, 97(7):2121-2129.
70. Zhang W., Zhang X., Fan X., et al. Effect of ICAM-1 and LFA-1 in hyperleukocytic acute myeloid leukaemia. Clin Lab Haematol 2006, 28(3):177-182.
71. Athale U.H., Chan A.K. Hemorrhagic complications in pediatric hematologic malignancies. Semin Thromb Hemost 2007, 33(4):408-415.
72. Majhail N.S., Lichtin A.E. Acute leukemia with a very high leukocyte count: confronting a medical emergency. Cleve Clin J Med 2004, 71(8):633-637.
73. Marbello L., Ricci F., Nosari A.M., et al. Outcome of hyperleukocytic adult acute myeloid leukaemia: a single-center retrospective study and review of literature. Leuk Res 2008, 32(8):1221-1227.
74. Szczepiorkowski Z.M., Bandarenko N., Kim H.C., et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apheresis 2007, 22(3):106-175.
75. Buchem M.A., Velde J., Willemze R., et al. Leucostasis, an underestimated cause of death in leukaemia. Ann Hematol 1988, 56(1):39-44.
76. Rowe J.M., Lichtman M.A. Hyperleukocytosis and leukostasis: common features of childhood chronic myelogenous leukemia. Blood 1984, 63(5):1230-1234.
77. Wu Y.K., Huang Y.C., Huang S.F., et al. Acute respiratory distress syndrome caused by leukemic infiltration of the lung. J Formos Med Assoc 2008, 107(5):419-423.
78. Azoulay E., Fieux F., Moreau D., et al. Acute monocytic leukemia presenting as acute respiratory failure. Am J Respir Crit Care Med 2003, 167(10):1329-1333.
79. Szyper-Kravitz M., Strahilevitz J., Oren V., et al. Pulmonary leukostasis: role of perfusion lung scan in diagnosis and follow up. Am J Hematol 2001, 67(2):136-138.
80. Ezzie M.E., Mastronarde J. Refractory hypoxia secondary to pulmonary leukostasis treated successfully with irradiation. Chest 2006, 130(4):332S-333S.
81. Kim H., Lee J.H., Choi S.J., et al. Analysis of fatal intracranial hemorrhage in 792 acute leukemia patients. Haematologica 2004, 89(5):622-624.
82. Tsai C.C., Huang C.B., Sheen J.M., et al. Sudden hearing loss as the initial manifestation of chronic myeloid leukemia in a child. Chang Gung Med J 2004, 27(8):629-633.
83. Hsu W.H., Chu S.J., Tsai W.C., et al. Acute myeloid leukemia presenting as one-and-a-half syndrome. Am J Emerg Med 2008, 26(4):513. e511-2.
84. Cukierman T., Gatt M.E., Libster D., et al. Chronic lymphocytic leukemia presenting with extreme hyperleukocytosis and thrombosis of the common femoral vein. Leuk Lymphoma 2002, 43(9):1865-1868.
85. Tallman M.S., Kwaan H.C. Intravascular clotting activation and bleeding in patients with hematologic malignancies. Rev Clin Exp Hematol 2004, 8(1):E1.
86. Li S., Salhany K.E. Spurious elevation of automated platelet counts in secondary acute monocytic leukemia associated with tumor lysis syndrome. Arch Pathol Lab Med 1999, 123(11):1111-1114.
87. Lele A.V., Mirski M.A., Stevens R.D., et al. Spurious hypoxemia. Crit Care Med 2005, 33(8):1854-1856.
88. Kolitz J.E. Acute leukemia in children. Conn's current therapy 2008, 446-453. Elsevier, Philadelphia. R. Rakel, E. Bope (Eds.).
89. Dutcher J.P., Schiffer C.A., Wiernik P.H. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol 1987, 5(9):1364-1372.
90. Kasner M.T., Laury A., Kasner S.E., et al. Increased cerebral blood flow after leukapheresis for acute myelogenous leukemia. Am J Hematol 2007, 82(12):1110-1112.
91. Lo-Coco F., Ammatuna E. Front line clinical trials and minimal residual disease monitoring in acute promyelocytic leukemia. Curr Top Microbiol Immunol 2007, 313:145-156.
92. Blum W., Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost 2007, 33(4):350-354.
93. Zarkovic M., Kwaan H.C. Correction of hyperviscosity by apheresis. Semin Thromb Hemost 2003, 29(5):535-542.
94. Thiebaut A., Thomas X., Belhabri A., et al. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol 2000, 79(9):501-506.
95. Bug G., Anargyrou K., Tonn T., et al. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion 2007, 47(10):1843-1850.
96. Schafer A.I. Thrombocytosis. N Engl J Med 2004, 350(12):1211-1219.
97. Keung Y.K., Owen J. Iron deficiency and thrombosis: literature review. Clin Appl Thromb Hemost 2004, 10(4):387-391.
98. Vannucchi A.M., Barbui T. Thrombocytosis and thrombosis. Hematology 2007, 2007(1):363-370.
99. Chomienne C., Rain J.D., Briere J., et al. Risk of leukemic transformation in PV and ET patients. Pathol Biol 2004, 52(5):289-293.
100. Spivak J.L. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004, 41(2 Suppl 3):1-5.
101. Sierko E., Wojtukiewicz M.Z. Platelets and angiogenesis in malignancy. Semin Thromb Hemost 2004, 30(1):95-108.
102. Tefferi A. Essential thrombocythemia: scientific advances and current practice. Curr Opin Hematol 2006, 13(2):93-98.
103. Thiele J., Kvasnicka H.M., Diehl V. Standardization of bone marrow features - does it work in hematopathology for histological discrimination of different disease patterns?. Histol Histopathol 2005, 20(2):633-644.
104. Levine R.L., Gilliland D.G. JAK-2 mutations and their relevance to myeloproliferative disease. Curr Opin Hematol 2007, 14(1):43-47.
105. Powner D.J., Hoots W.K. Thrombocytosis in the NICU. Neurocrit Care 2008, 8(3):471-475.
106. van der Meer W., MacKenzie M.A., Dinnissen J.W.B., et al. Pseudoplatelets: a retrospective study of their incidence and interference with platelet counting. J Clin Pathol 2003, 56(10):772-774.
107. Frenkel E.P., Mammen E.F. Sticky platelet syndrome and thrombocythemia. Hematol Oncol Clin North Am 2003, 17(1):63-83.
108. Sevastos N., Theodossiades G., Efstathiou S., et al. Pseudohyperkalemia in serum: the phenomenon and its clinical magnitude. J Lab Clin Med 2006, 147(3):139-144.
109. Briere J.B. Essential thrombocythemia. Orphanet J Rare Dis 2007, 2:3.
110. Kessler C.M. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders. Semin Hematol 2004, 41(2 Suppl 3):10-14.
111. Harrison C.N., Campbell P.J., Buck G., et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005, 353(1):33-45.
112. Dingli D., Tefferi A. A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Leuk Lymphoma 2005, 46(5):641-650.
113. Barosi G., Mesa R.A., Thiele J., et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008, 22(2):437-438.